Efficacy of diltiazem 2% rectal gel in the treatment of chronic anal fissure: a retrospective observational study.

Cirugia y cirujanos Pub Date : 2024-01-01 DOI:10.24875/CIRU.22000626

Gabriel Martínez-Orea, Francisco J Rodríguez-Lucena, Celia García-González, Nieves Cano-Cuenca, Ana Candela-Fajardo, Rodrigo Bonilla-Peñarrubia

{"title":"Efficacy of diltiazem 2% rectal gel in the treatment of chronic anal fissure: a retrospective observational study.","authors":"Gabriel Martínez-Orea, Francisco J Rodríguez-Lucena, Celia García-González, Nieves Cano-Cuenca, Ana Candela-Fajardo, Rodrigo Bonilla-Peñarrubia","doi":"10.24875/CIRU.22000626","DOIUrl":null,"url":null,"abstract":"Objective: The aim of this study is to describe the effectiveness and safety of a magistral formulation of diltiazem 2% rectal gel as a treatment for chronic anal fissure.Material and methods: A retrospective observational study of all patients that began treatment with diltiazem 2% gel during 2019. The primary endpoint of the study was anal fissure healing. We also looked for differences in effectiveness between those initiating treatment and those who had been previously treated, long-term effectiveness through a 2-year follow-up and frequency of adverse effects.Results: Of the 166 patients included in the study, anal fissure healed in 72.9%. We detected adverse effects in 12 patients, the most common was local irritation. After 2 years of follow-up, 88% of patients did not relapse.Conclusion: In this study, use of topical diltiazem 2% has been shown to be effective and safe in the treatment of anal fissure and should be considered as the first line of therapy.","PeriodicalId":93936,"journal":{"name":"Cirugia y cirujanos","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cirugia y cirujanos","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24875/CIRU.22000626","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: The aim of this study is to describe the effectiveness and safety of a magistral formulation of diltiazem 2% rectal gel as a treatment for chronic anal fissure.

Material and methods: A retrospective observational study of all patients that began treatment with diltiazem 2% gel during 2019. The primary endpoint of the study was anal fissure healing. We also looked for differences in effectiveness between those initiating treatment and those who had been previously treated, long-term effectiveness through a 2-year follow-up and frequency of adverse effects.

Results: Of the 166 patients included in the study, anal fissure healed in 72.9%. We detected adverse effects in 12 patients, the most common was local irritation. After 2 years of follow-up, 88% of patients did not relapse.

Conclusion: In this study, use of topical diltiazem 2% has been shown to be effective and safe in the treatment of anal fissure and should be considered as the first line of therapy.

查看原文本刊更多论文

2% 地尔硫卓直肠凝胶治疗慢性肛裂的疗效：一项回顾性观察研究。

研究目的本研究旨在描述2%地尔硫卓直肠凝胶口服制剂治疗慢性肛裂的有效性和安全性：对2019年期间开始使用2%地尔硫卓凝胶治疗的所有患者进行回顾性观察研究。研究的主要终点是肛裂愈合。我们还观察了开始治疗者与之前接受过治疗者的疗效差异、2年随访的长期疗效以及不良反应发生频率：结果：在参与研究的 166 名患者中，72.9% 的肛裂患者痊愈。我们发现12名患者出现了不良反应，最常见的是局部刺激。经过两年的随访，88%的患者没有复发：这项研究表明，局部使用 2% 地尔硫卓治疗肛裂既有效又安全，应将其作为一线疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cirugia y cirujanos

自引率

0.00%

发文量